- Home
- ALLT vs CAPR Comparison
ALLT vs CAPR Comparison
Compare ALLT & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLT
- CAPR
- Stock Information
- Founded
- ALLT 1996
- CAPR 2005
- Country
- ALLT Israel
- CAPR United States
- Employees
- ALLT N/A
- CAPR N/A
- Industry
- ALLT Telecommunications Equipment
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALLT Telecommunications
- CAPR Health Care
- Exchange
- ALLT Nasdaq
- CAPR Nasdaq
- Market Cap
- ALLT 342.5M
- CAPR 322.7M
- IPO Year
- ALLT 2006
- CAPR N/A
- Fundamental
- Price
- ALLT $7.79
- CAPR $7.10
- Analyst Decision
- ALLT Buy
- CAPR Strong Buy
- Analyst Count
- ALLT 1
- CAPR 8
- Target Price
- ALLT N/A
- CAPR $24.75
- AVG Volume (30 Days)
- ALLT 509.7K
- CAPR 1.7M
- Earning Date
- ALLT 08-14-2025
- CAPR 08-11-2025
- Dividend Yield
- ALLT N/A
- CAPR N/A
- EPS Growth
- ALLT N/A
- CAPR N/A
- EPS
- ALLT N/A
- CAPR N/A
- Revenue
- ALLT $95,342,000.00
- CAPR $13,392,150.00
- Revenue This Year
- ALLT $9.08
- CAPR $16.24
- Revenue Next Year
- ALLT $26.37
- CAPR $328.11
- P/E Ratio
- ALLT N/A
- CAPR N/A
- Revenue Growth
- ALLT 4.74
- CAPR N/A
- 52 Week Low
- ALLT $2.75
- CAPR $3.98
- 52 Week High
- ALLT $10.77
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- ALLT 51.15
- CAPR 42.24
- Support Level
- ALLT $7.05
- CAPR $6.90
- Resistance Level
- ALLT $8.10
- CAPR $8.00
- Average True Range (ATR)
- ALLT 0.40
- CAPR 0.55
- MACD
- ALLT 0.04
- CAPR -0.02
- Stochastic Oscillator
- ALLT 70.48
- CAPR 7.91
About ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.